Deubiquitylation of Deubiquitylases.Pdf
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated. -
Deubiquitinases in Cancer: New Functions and Therapeutic Options
Oncogene (2012) 31, 2373–2388 & 2012 Macmillan Publishers Limited All rights reserved 0950-9232/12 www.nature.com/onc REVIEW Deubiquitinases in cancer: new functions and therapeutic options JM Fraile1, V Quesada1, D Rodrı´guez, JMP Freije and C Lo´pez-Otı´n Departamento de Bioquı´mica y Biologı´a Molecular, Facultad de Medicina, Instituto Universitario de Oncologı´a, Universidad de Oviedo, Oviedo, Spain Deubiquitinases (DUBs) have fundamental roles in the Hunter, 2010). Consistent with the functional relevance ubiquitin system through their ability to specifically of proteases in these processes, alterations in their deconjugate ubiquitin from targeted proteins. The human structure or in the mechanisms controlling their genome encodes at least 98 DUBs, which can be grouped spatiotemporal expression patterns and activities cause into 6 families, reflecting the need for specificity in diverse pathologies such as arthritis, neurodegenerative their function. The activity of these enzymes affects the alterations, cardiovascular diseases and cancer. Accord- turnover rate, activation, recycling and localization ingly, many proteases are an important focus of of multiple proteins, which in turn is essential for attention for the pharmaceutical industry either as drug cell homeostasis, protein stability and a wide range of targets or as diagnostic and prognostic biomarkers signaling pathways. Consistent with this, altered DUB (Turk, 2006; Drag and Salvesen, 2010). function has been related to several diseases, including The recent availability of the genome sequence cancer. Thus, multiple DUBs have been classified as of different organisms has facilitated the identification oncogenes or tumor suppressors because of their regula- of their entire protease repertoire, which has been tory functions on the activity of other proteins involved in defined as degradome (Lopez-Otin and Overall, 2002). -
Pathways of Cellular Proteostasis in Aging and Disease
JCB: Review Pathways of cellular proteostasis in aging and disease Courtney L. Klaips, Gopal Gunanathan Jayaraj, and F. Ulrich Hartl Department of Cellular Biochemistry, Max Planck Institute of Biochemistry, Martinsried, Germany Ensuring cellular protein homeostasis, or proteostasis, re- control of abundance and subcellular localization, and finally, quires precise control of protein synthesis, folding, confor- disposal by degradation. A complex proteostasis network (PN) acts at each of these mational maintenance, and degradation. A complex and steps to maintain a balanced proteome linked by molecular adaptive proteostasis network coordinates these processes chaperones of different classes as central players. These factors with molecular chaperones of different classes and their ensure de novo folding in a crowded cellular environment and regulators functioning as major players. This network maintain proteins in a soluble, nonaggregated state. Moreover, in conditions that disfavor folding or solubility, certain chaper- serves to ensure that cells have the proteins they need ones act to target misfolded proteins for degradation or spatial while minimizing misfolding or aggregation events that sequestration, thus protecting the rest of the proteome from ab- are hallmarks of age-associated proteinopathies, includ- errant interactions (Balchin et al., 2016; Sontag et al., 2017). Here, we describe the major pathways of cellular pro- ing neurodegenerative disorders such as Alzheimer’s and teostasis and outline the challenges they face during aging and Parkinson’s diseases. It is now clear that the capacity of disease. We exemplify these processes using mainly the proteo- cells to maintain proteostasis undergoes a decline during stasis pathways operating in the cytosol, where most cellular aging, rendering the organism susceptible to these pa- proteins are produced. -
Deubiquitylases in Developmental Ubiquitin Signaling and Congenital Diseases
Cell Death & Differentiation (2021) 28:538–556 https://doi.org/10.1038/s41418-020-00697-5 REVIEW ARTICLE Deubiquitylases in developmental ubiquitin signaling and congenital diseases 1 1,2 1 Mohammed A. Basar ● David B. Beck ● Achim Werner Received: 16 October 2020 / Revised: 20 November 2020 / Accepted: 24 November 2020 / Published online: 17 December 2020 This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply 2020 Abstract Metazoan development from a one-cell zygote to a fully formed organism requires complex cellular differentiation and communication pathways. To coordinate these processes, embryos frequently encode signaling information with the small protein modifier ubiquitin, which is typically attached to lysine residues within substrates. During ubiquitin signaling, a three-step enzymatic cascade modifies specific substrates with topologically unique ubiquitin modifications, which mediate changes in the substrate’s stability, activity, localization, or interacting proteins. Ubiquitin signaling is critically regulated by deubiquitylases (DUBs), a class of ~100 human enzymes that oppose the conjugation of ubiquitin. DUBs control many essential cellular functions and various aspects of human physiology and development. Recent genetic studies have fi 1234567890();,: 1234567890();,: identi ed mutations in several DUBs that cause developmental disorders. Here we review principles controlling DUB activity and substrate recruitment that allow these enzymes to regulate ubiquitin signaling during development. We summarize key mechanisms of how DUBs control embryonic and postnatal differentiation processes, highlight developmental disorders that are caused by mutations in particular DUB members, and describe our current understanding of how these mutations disrupt development. Finally, we discuss how emerging tools from human disease genetics will enable the identification and study of novel congenital disease-causing DUBs. -
Personalized Diagnostics
The Center for PERSONALIZED DIAGNOSTICS Precision Diagnostics for Personalized Medicine PennMedicine.org/CPD | 215.615.3966 The Center for Personalized Diagnostics (CPD) is a joint initiative between Penn Medicine’s Department of Pathology and Laboratory Medicine and the Abramson Cancer Center. The Center integrates molecular genetics, pathology informatics and genomic pathology to develop personalized diagnostic profiles for individuals with cancer. The CPD offers the highest volume of genome testing in the region. PENNSEQTM HEMATOLOGIC MALIGNANCIES PANEL ABL1 CD79A FANCA IKZF1 NOTCH1 RIT1 TERT ASXL1 CD79B FANCC IL7R NOTCH2 RPS15 TET2 ATM CDKN2A FANCD2 JAK2 NPM1 RRAGC TNFAIP3 B2M CEBPA FANCE JAK3 NRAS RUNX1 TNFRSF14 BCL2 CIITA FANCF KIT PALB2 SETBP1 TP53 BCOR CREBBP FANCG KLF2 PDGFRA SF1 TPMT BCORL1 CSF1R FANCL KLHL6 PHF6 SF3A1 TRAF3 BIRC3 CSF3R FANCM KRAS PLCG1 SF3B1 U2AF1 BRAF CXCR4 FBXW7 MAP2K1 PLCG2 SLX4 U2AF2 BRCA1 DDX3X FLT3 MAPK1 POT1 SMC1A WT1 BRCA2 DDX41 GATA2 MIR142 PRPF40B SOCS1 XPO1 BRINP3 DICER1 GNA13 MPL PTEN SRSF2 XRCC2 BRIP1 DNMT3A GNAS MYC PTPN11 STAG2 ZMYM3 BTK EGR2 HNRNPK MYCN RAD21 STAT3 ZRSR2 CALR ERCC4 ID3 MYD88 RAD51 STAT5B CARD11 ETV6 IDH1 NF1 RAD51C TBL1XR1 CBL EZH2 IDH2 NFKBIE RHOA TCF3 • Accepted Specimens: Blood; bone marrow; formalin-fixed, paraffin-embedded (FFPE) • Detects: Single nucleotide variants (SNVs); small indels; copy number gains in ABL1, tissue; fresh tissue in PreservCyt PDGFRA, and MYC • Minimum Requirements: 10% tumor nuclei for tissue, 100ng of DNA (non-FFPE), 200ng • Limitations: Lower limit -
Protein Homeostasis, Second Edition
This is a free sample of content from Protein Homeostasis, Second Edition. Click here for more information on how to buy the book. Index A overview of diseases, 13, 41–43 Abf2, 160 polyphosphate AD. See Alzheimer’s disease amyloidogenic protein interactions, 393–395 AFG3L2, 162 cytotoxicity amelioration, 396–397 Africa swine fever virus (ASFV), 468 prospects for study, 52, 55 Aging protein homeostasis context, 48–49 heat shock factors, 431 structure–activity relationship, 14–15 proteostasis network regulation, 450–452 therapeutic intervention, 50–52 Ago2, 335, 467 toxicity, 47–48 Aha1, 333, 335, 338–339, 504 Amyotrophic lateral sclerosis (ALS), 214, 262, 264, AIRAP, 267 290–291, 293, 404, 409, 524, 532 AIRAPL, 267–268 ApoB, 135 AKT, 274, 467 ASFV. See Africa swine fever virus ALK, 503 ATAD1, 104 ALMC2, 487 ATF4, 79, 88, 182, 186, 189, 445–446 ALP. See Autophagy lysosome pathway ATF5, 182, 186, 189 a-Synuclein, 375, 522 ATF6, 60, 62–64, 79, 445–446, 481–482, 484–489 ALS. See Amyotrophic lateral sclerosis ATFS-1, 99, 180–181, 185, 188–189, 445–446 Alzheimer’s disease (AD), 186, 519 Atg7, 293 autophagy lysosomal pathway, 290–291 Atg32, 167 chaperone studies, 213–214, 216–217, 222 ATM, 313 Hsp90 studies, 337 ATR, 313 polyphosphate studies, 392, 394–395, 399 Atropine, 501 AMPK, 444 ATXN2, 524 Amyloid Autophagy lysosome pathway (ALP) chaperone modulation chaperone-mediated autophagy, 288–289 aggregation prevention, 217–222 history of study, 285 degradation of amyloid-forming proteins, 225–227 macroautophagy, 287–288 disaggregation of amyloids, -
Functional Modules of the Proteostasis Network
Downloaded from http://cshperspectives.cshlp.org/ on September 28, 2021 - Published by Cold Spring Harbor Laboratory Press Functional Modules of the Proteostasis Network Gopal G. Jayaraj, Mark S. Hipp, and F. Ulrich Hartl Department of Cellular Biochemistry, Max Planck Institute of Biochemistry, Am Klopferspitz 18, 82152 Martinsried, Germany Correspondence: [email protected] Cells invest in an extensive network of factors to maintain protein homeostasis (proteostasis) and prevent the accumulation of potentially toxic protein aggregates. This proteostasis network (PN) comprises the machineries for the biogenesis, folding, conformational mainte- nance, and degradation of proteins with molecular chaperones as central coordinators. Here, we review recent progress in understanding the modular architecture of the PN in mammalian cells and how it is modified during cell differentiation. We discuss the capacity and limitations of the PN in maintaining proteome integrity in the face of proteotoxic stresses, such as aggregate formation in neurodegenerative diseases. Finally, we outline various pharmaco- logical interventions to ameliorate proteostasis imbalance. roteins are the most versatile macromole- 1999; Hartl and Hayer-Hartl 2009). However, Pcules and responsible for almost all cellular proteins with complex domain folds and multi- functions. An average human cell expresses domain proteins, which make up the major part ∼10,000–13,000 different protein species (Bek- of the proteome, frequently populate folding in- ker-Jensen et al. 2017; Kulak et al. 2017) with termediates that expose hydrophobic amino acid copy numbers varying over several orders of residues. These proteins are at risk of misfolding magnitude, from afew molecules to tens of thou- and aggregation within the highly crowded en- sands. -
Supplementary Material Contents
Supplementary Material Contents Immune modulating proteins identified from exosomal samples.....................................................................2 Figure S1: Overlap between exosomal and soluble proteomes.................................................................................... 4 Bacterial strains:..............................................................................................................................................4 Figure S2: Variability between subjects of effects of exosomes on BL21-lux growth.................................................... 5 Figure S3: Early effects of exosomes on growth of BL21 E. coli .................................................................................... 5 Figure S4: Exosomal Lysis............................................................................................................................................ 6 Figure S5: Effect of pH on exosomal action.................................................................................................................. 7 Figure S6: Effect of exosomes on growth of UPEC (pH = 6.5) suspended in exosome-depleted urine supernatant ....... 8 Effective exosomal concentration....................................................................................................................8 Figure S7: Sample constitution for luminometry experiments..................................................................................... 8 Figure S8: Determining effective concentration ......................................................................................................... -
The Proteasomal Deubiquitinating Enzyme PSMD14 Regulates Macroautophagy by Controlling Golgi-To-ER Retrograde Transport
Supplementary Materials The proteasomal deubiquitinating enzyme PSMD14 regulates macroautophagy by controlling Golgi-to-ER retrograde transport Bustamante HA., et al. Figure S1. siRNA sequences directed against human PSMD14 used for Validation Stage. Figure S2. Primer pairs sequences used for RT-qPCR. Figure S3. The PSMD14 DUB inhibitor CZM increases the Golgi apparatus area. Immunofluorescence microscopy analysis of the Golgi area in parental H4 cells treated for 4 h either with the vehicle (DMSO; Control) or CZM. The Golgi marker GM130 was used to determine the region of interest in each condition. Statistical significance was determined by Student's t-test. Bars represent the mean ± SEM (n =43 cells). ***P <0.001. Figure S4. CZM causes the accumulation of KDELR1-GFP at the Golgi apparatus. HeLa cells expressing KDELR1-GFP were either left untreated or treated with CZM for 30, 60 or 90 min. Cells were fixed and representative confocal images were acquired. Figure S5. Effect of CZM on proteasome activity. Parental H4 cells were treated either with the vehicle (DMSO; Control), CZM or MG132, for 90 min. Protein extracts were used to measure in vitro the Chymotrypsin-like peptidase activity of the proteasome. The enzymatic activity was quantified according to the cleavage of the fluorogenic substrate Suc-LLVY-AMC to AMC, and normalized to that of control cells. The statistical significance was determined by One-Way ANOVA, followed by Tukey’s test. Bars represent the mean ± SD of biological replicates (n=3). **P <0.01; n.s., not significant. Figure S6. Effect of CZM and MG132 on basal macroautophagy. (A) Immunofluorescence microscopy analysis of the subcellular localization of LC3 in parental H4 cells treated with either with the vehicle (DMSO; Control), CZM for 4 h or MG132 for 6 h. -
Supplementary Data ASXL2 Regulates Hematopoiesis in Mice and Its
Supplementary data ASXL2 regulates hematopoiesis in mice and its deficiency promotes myeloid expansion Supplementary Methods Genomic DNA extraction Genomic DNA was extracted from BM mononuclear cells using a DNA extraction kit (Puregene Gentra System, Minneapolis, MN, USA) according to the manufacturer’s instructions. Genomic DNA was quantified using Qubit Fluorometer (Life Technologies) and DNA integrity was assessed by agarose gel electrophoresis. For samples with low quantity, DNA was amplified using REPLI-g Ultrafast mini kit (Qiagen). Peripheral blood analysis Complete peripheral blood counts were analysed using Abbott Cell-Dyn 3700 hematology analyzer (Abbott Laboratories). Expression analysis of Asxl2 and Asxl1 Transcript levels of Asxl2 and Asxl1 were estimated using quantitative RT-PCR with following primers: Asxl2 primer set 1, ATTCGACAAGAGATTGAGAAGGAG (forward) and TTTCTGTGAATCTTCAAGGCTTAG (reverse); Asxl2 primer set 2, GCCCTTAACAATGAGTTCTTCACT (forward) and TCCACAGCTCTACTTTCTTCTCCT (reverse); Asxl1 primers, GGTGGAACAATGGAAGGAAA (forward) and CTGGCCGAGAACGTTTCTTA (reverse). Asxl2 protein was detected in immunoblot using anti-ASXL2 antibody (Bethyl). In vitro differentiation of bone marrow cells Bone marrow (BM) cells were cultured in IMDM containing 20% FBS and 10 ng/ml IL3, 10 ng/ml IL6, 20 ng/ml SCF and 20 ng/ml GMCSF for two weeks. For FACS analysis, cells were washed, stained with fluorochrome-conjugated antibodies and analysed on FACS LSR II flow cytometer (BD Biosciences) using FACSDIVA software (BD Biosciences). Colony re-plating assay Bone marrow cells were plated in methylcellulose medium containing mouse stem cell factor (SCF), mouse interleukin 3 (IL-3), human interleukin 6 (IL-6) and human erythropoietin (MethoCult GF M3434; StemCell Technologies). Colonies were enumerated after 9-12 days and cells were harvested for re-plating. -
UBE2O Is a Quality Control Factor for Orphans of Multi-Protein Complexes
RESEARCH ◥ factors. A transmembrane (TM) domain inter- REPORT rupted by three basic residues (hereafter termed 3R) (fig. S1A) is not recognized by quality control factors specialized for mislocalized membrane PROTEOSTASIS proteins, such as BAG6 or the ubiquilin family members (5–7); yet, 3R was ubiquitinated sim- ilarly to a BAG6 substrate (fig. S1B). Although 3R UBE2O is a quality control factor for is an artificial mutant, we reasoned that mech- anistic dissection of its ubiquitination pathway orphans of multiprotein complexes mightleadustoaqualitycontrolpathwayand provide tools that could be exploited to identify physiological substrates. † Kota Yanagitani,* Szymon Juszkiewicz, Ramanujan S. Hegde In vitro–translated 35S-labeled 3R immunopu- rified under native conditions became modified Many nascent proteins are assembled into multiprotein complexes of defined stoichiometry. with His-ubiquitin in the presence of recombinant Imbalances in the synthesis of individual subunits result in orphans. How orphans are selectively E1, E2 (UBCH5), and adenosine 5′-triphosphate eliminated to maintain protein homeostasis is poorly understood. Here, we found that the (ATP) (fig. S1, C and D), indicating that the im- conserved ubiquitin-conjugating enzyme UBE2O directly recognized juxtaposed basic and munopurified complexes contained a ubiquitin hydrophobic patches on unassembled proteins to mediate ubiquitination without a separate ligase. The primary 3R-associated ubiquitination a ubiquitin ligase. In reticulocytes, where UBE2O is highly up-regulated, unassembled -globin activity had a native molecular weight of ~150 to b molecules that failed to assemble with -globin were selectively ubiquitinated by UBE2O. In 300 kD (Fig. 1, A and B). Cross-linking reactions Downloaded from nonreticulocytes, ribosomal proteins that did not engage nuclear import factors were targets for of the active fractions revealed interacting part- UBE2O. -
For Personal Use. Only Reproduce with Permission from the Lancet
Correlation to non-HGNT Accesion group 2 Description AA897204 1.479917 ESTs T85111 1.286576 null T60168 | AI821353 1.274487 thyroid transcription factor 1 AA600173 1.183065 ubiquitin-conjugating enzyme E2A (RAD6 homolog) R55745 1.169339 ELAV (embryonic lethal, abnormal vision, Drosophila)-like 4 (Hu antigen D) AA400492 1.114935 ESTs AA864791 1.088826 hypothetical protein FLJ21313 N53758 1.070402 EST AI216628 1.067763 ESTs AI167637 1.058561 ESTs AA478265 1.056331 similar to transmembrane receptor Unc5H1 AA969924 1.039315 EST AI074650 1.039043 hypothetical protein FLJ13842 R20763 1.035807 ELAV (embryonic lethal, abnormal vision, Drosophila)-like 3 (Hu antigen C) AI347081 1.034518 Ca2+-dependent activator protein for secretion R44386 1.028005 ESTs AA976699 1.027227 chromogranin A (parathyroid secretory protein 1) AA634475 1.026766 KIAA1796 protein AA496809 1.02432 SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 1 H16572 1.013059 null H29013 1.002117 seizure related 6 homolog (mouse)-like AI299731 1.001053 Homo sapiens nanos mRNA, partial cds AA400194 0.9950039 EST AI216537 | AI820870 0.9737153 Homo sapiens cDNA FLJ39674 fis, clone SMINT2009505 AA426408 0.9728649 type I transmembrane receptor (seizure-related protein) AA971742 | AI733380 0.9707561 achaete-scute complex-like 1 (Drosophila) R41450 0.9655133 ESTs AA487505 0.9636143 immunoglobulin superfamily, member 4 AA404337 0.957686 thymus high mobility group box protein TOX N68578 0.9552571 ESTs R45008 0.9422938 ELAV (embryonic lethal, abnormal